Good evening :)
Wockhardt Limited

Wockhardt Limited

WOCKPHARMA Share Price

NSE
₹1,868.001.50% (-28.50)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹30,820 cr, stock is ranked 277

Stock is 3.48x as volatile as Nifty

WOCKPHARMA Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹30,820 cr, stock is ranked 277

Stock is 3.48x as volatile as Nifty

WOCKPHARMA Performance & Key Metrics

WOCKPHARMA Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
75.175.84—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
43.095.770.50%

WOCKPHARMA Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

WOCKPHARMA Company Profile

Wockhardt Limited manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Investor Presentation

View older View older 

Jun 4, 2026

PDF
View Older Presentations

WOCKPHARMA Similar Stocks (Peers)

Compare with peers Compare with peers 

WOCKPHARMA Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
34.03
34.03
1Y Return
4.17%
4.17%
Buy Reco %
93.33
93.33
PE Ratio
79.41
79.41
1Y Return
27.30%
27.30%
Buy Reco %
85.19
85.19
LAURUSLABS
PE Ratio
142.74
142.74
1Y Return
136.41%
136.41%
Buy Reco %
61.54
61.54
PE Ratio
22.78
22.78
1Y Return
26.40%
26.40%
Buy Reco %
57.69
57.69
PE Ratio
27.47
27.47
1Y Return
7.91%
7.91%
Buy Reco %
62.86
62.86
Compare with Peers

WOCKPHARMA Sentiment Analysis

WOCKPHARMA Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

WOCKPHARMA Stock Summary · June 2026

Management presented the quarter as the culmination of a difficult, transformation‑led repositioning that delivered materially stronger profitability and liquidity, with revenue of INR 3,373 crore and an expanded EBITDA margin of about 18.6%. They emphasised disciplined cost‑efficiency—nearly 50 projects, supply‑chain and manufacturing restructuring, a new S/4HANA ERP and AI pilots—and a strategic pivot toward innovation with specialty products including a biosimilars diabetes focus and the newly FDA‑approved anti‑infective, Zaynich. That approval, a label covering Enterobacterales and Pseudomonas and patent protection to 2038 plus QIDP exclusivity, underpins a self‑commercial U.S. launch supported by partner execution and an integrated medical/sales/market‑access model; management expects the Zaynich unit may be slightly loss‑making or breakeven for 12–18 months while upfront launch costs are absorbed. They flagged tension between near‑term investment and longer‑term upside — including regulatory timing and building a new commercial organization — and reiterated near‑term plans of INR 200–300 crore capex, steady R&D spend and an anticipated commercial inflection around 12–18 months, with directional peak Zaynich revenues of $1.5–$2.0 billion.

WOCKPHARMA Stock Growth Drivers
WOCKPHARMA Stock Growth Drivers
8
  • Regulatory and IP Milestones Establishing Market Exclusivity

    The company has secured major regulatory and intellectual-property milestones that materially de-risk commercialization. The novel

  • Strong and Differentiated Clinical Evidence Supporting Zaynich

    Clinical and real‑world datasets demonstrate compelling efficacy and a differentiated mechanism for the cefepime–zidebactam combination,

WOCKPHARMA Stock Challenges
WOCKPHARMA Stock Challenges
5
  • Commercialization execution risk and near‑term profitability pressure

    Bringing the lead antibiotic to market requires building a fundamentally different commercial organization than the

  • Regulatory and clinical development delays and uncertainty

    Multiple regulatory and development headwinds create timing and execution uncertainty across the pipeline. One combination

WOCKPHARMA Forecast

WOCKPHARMA Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

WOCKPHARMA

WOCKPHARMA

Income

Balance Sheet

Cash Flow

WOCKPHARMA Income Statement

WOCKPHARMA Income Statement

Loading...

Quarterjun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026sep 2026
Total Revenue769.00818.00729.00758.00758.00803.00913.001,032.00960.00980.00
Operating & Other expensessubtract648.00699.00593.00679.00763.00604.00721.00740.00737.00796.00
Depreciation/Amortizationsubtract54.0055.0055.0053.0056.0053.0065.0053.0055.0055.00
Interest & Other Itemssubtract73.0073.0060.0048.0048.0055.0060.0050.0052.0056.00
Taxes & Other Itemssubtract8.0013.007.003.00-19.0013.008.0023.0010.00-6.00
EPS-0.95-1.470.91-1.57-5.534.813.6110.236.554.85

WOCKPHARMA Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual report

PDF

Investor Presentation

Jun 4PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

Jun 5PDF
Jun 5PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

Feb 21PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

Mar 8PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
 

WOCKPHARMA Stock Peers

WOCKPHARMA Past Performance & Peer Comparison

WOCKPHARMA Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Wockhardt Limited108.505.84—
Sun Pharmaceutical Industries Limited34.035.060.90%
Torrent Pharmaceuticals Ltd79.419.940.74%
Laurus Labs Ltd142.7423.360.09%
ScreenerCompare valuation on Screener

WOCKPHARMA Stock Price Comparison

Compare WOCKPHARMA with any stock or ETF
Compare WOCKPHARMA with any stock or ETF
WOCKPHARMA
Loading...

WOCKPHARMA Holdings

WOCKPHARMA Shareholdings

WOCKPHARMA Promoter Holdings Trend

WOCKPHARMA Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

WOCKPHARMA Institutional Holdings Trend

WOCKPHARMA Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

WOCKPHARMA Shareholding Pattern

WOCKPHARMA Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding49.32%5.99%3.01%7.02%34.66%

Dec 2025

Mar 2026

Jun 2026

Sep 2026

WOCKPHARMA Shareholding History

WOCKPHARMA Shareholding History

JunSepDec '25MarJunSep7.29%7.10%6.99%7.09%7.22%7.02%

Mutual Funds Invested in WOCKPHARMA

Mutual Funds Invested in WOCKPHARMA

No mutual funds holding trends are available

Top 5 Mutual Funds holding Wockhardt Limited




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.4420%3.36%0.11%7/69 (+1)
0.8119%1.35%-0.09%71/117 (0)
0.6721%2.86%0.45%12/59 (+2)

Compare 3-month MF holding change on Screener

WOCKPHARMA Insider Trades & Bulk Stock Deals

WOCKPHARMA Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing WOCKPHARMA stock

smallcases containing WOCKPHARMA stock

Looks like this stock is not in any smallcase yet.

WOCKPHARMA Events

WOCKPHARMA Events

WOCKPHARMA Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

WOCKPHARMA has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

WOCKPHARMA Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

WOCKPHARMA has not given any dividends in last 5 years

WOCKPHARMA Upcoming Dividends

WOCKPHARMA Upcoming Dividends

No upcoming dividends are available

WOCKPHARMA Past Dividends

WOCKPHARMA Past Dividends

Cash Dividend

Ex DateEx DateNov 17, 2016

Interim
Interim | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Nov 17, 2016

Cash Dividend

Ex DateEx DateNov 13, 2014

Interim
Interim | Div/Share: ₹20.00

Dividend/Share

₹20.00

Ex DateEx Date

Nov 13, 2014

Cash Dividend

Ex DateEx DateFeb 17, 2014

Interim 2
Interim 2 | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Feb 17, 2014

Cash Dividend

Ex DateEx DateNov 7, 2013

Interim
Interim | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Nov 7, 2013

Cash Dividend

Ex DateEx DateAug 22, 2013

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 22, 2013

WOCKPHARMA Stock News & Opinions

WOCKPHARMA Stock News & Opinions

Earnings
Earnings
Wockhardt Ltd consolidated sales up 4.31% on year in Q3FY2026

Wockhardt Ltd share price declined by 0.21% to Rs 1892.15 after the company's net profit plunged by 31.78% to Rs 73.0 crore, while revenue from operations slightly gained 4.31% to Rs 969.0 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, easing 4.75%. It has marginally improved by 2.16% over last one week and moved up slightly by 0.86% in last one month while the market capitalization of Wockhardt Ltd has inched up 0.40% and 6.12% in the same period respectively. Profit before tax (PBT) of Wockhardt Ltd stood at Rs 73.0 crore in Q3 FY26, crashing by 19.78% year-on-year, and tanking 37.07% quarter-on-quarter. EBITDA came in at Rs 162 crore, rising 3.18% YoY and gaining 0.62% sequentially. Total expenses grew marginally by 7.45% to Rs 851.0 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 243.0 crore, inching up 4.29% YoY, while employee benefits expense was at Rs 201.0 crore, softening 0.99% YoY. For the TTM ended FY26, revenue from operations improved 11.99% to Rs 3373.0 crore, while net profit witnessed a sharp fall of 449.12% to Rs 199.0 crore, compared to previous TTM. EBITDA soared by 34000% to Rs 541.0 crore, and PBT collapsed by 1587.50% to Rs 238.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 390.0 crore in FY26, as against Rs 22.0 crore in FY25. Wockhardt Ltd jumped 33.73% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 9.87% during the same period.

4 hours agoCapital Market - Live
Spotlight
Spotlight
Wockhardt Ltd gains for third straight session

Wockhardt Ltd gained for a third straight session today. The stock is quoting at Rs 1912.9, up 1.49% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73339.6, down 0.35%. Wockhardt Ltd has slipped around 12.82% in last one month. Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has slipped around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 3.39 lakh shares today, compared to the daily average of 6.96 lakh shares in last one month.The PE of the stock is 92.53 based on TTM earnings ending June 26.

6 days agoCapital Market - Live
Corporate
Corporate
Wockhardt Limited’s committee allotted 20,000 equity shares under its Employee Stock Options Scheme

Wockhardt Limited announced that its Share Allotment Committee has allotted 20,000 equity shares with a face value of Rs 5 each on October 27, 2026, pursuant to the exercise of stock options under the Employee Stock Options Scheme - 2011. Consequently, the company's paid-up equity share capital increased from Rs 81,24,60,845 consisting of 16,24,92,169 equity shares to Rs 81,25,60,845 consisting of 16,25,12,169 equity shares.

1 week agoCapital Market - Live
Corporate
Corporate
Wockhardt to review financial results for quarter and half year ending September 30, 2026

Wockhardt Limited will hold a board meeting on Monday, November 2, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026, according to a regulatory filing. The trading window for the company's shares, which was closed from Thursday, October 1, 2026, will remain closed until 48 hours after the financial results are declared on November 2, 2026.

1 week agoCapital Market - Live
Spotlight
Spotlight
Wockhardt Ltd slips for fifth straight session

Wockhardt Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1961.5, down 0.09% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.81% on the day, quoting at 22544.1. The Sensex is at 72458.04, up 0.74%.Wockhardt Ltd has lost around 4.97% in last one month.Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has eased around 1.02% in last one month and is currently quoting at 26078.85, down 0.6% on the day. The volume in the stock stood at 8.04 lakh shares today, compared to the daily average of 10.23 lakh shares in last one month.The PE of the stock is 96.43 based on TTM earnings ending June 26.

3 weeks agoCapital Market - Live
Corporate
Corporate
Wockhardt Limited received a certificate confirming securities handling compliance from MUFG Intime India

Wockhardt Limited informed the BSE Limited and National Stock Exchange of India Limited that it received a certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, confirming the handling of securities received for dematerialization during the quarter ended September 30, 2026, in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

3 weeks agoCapital Market - Live
Corporate
Corporate
Wockhardt closes equity share trading window ahead of financial results declaration

Wockhardt Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in equity shares of the company will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.

1 month agoCapital Market - Live
Spotlight
Spotlight
Wockhardt Ltd up for third straight session

Wockhardt Ltd gained for a third straight session today. The stock is quoting at Rs 2188.7, up 4.92% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74818.76, up 0.71%. Wockhardt Ltd has risen around 15.13% in last one month. Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has risen around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 11.93 lakh shares today, compared to the daily average of 11.81 lakh shares in last one month.The PE of the stock is 102.45 based on TTM earnings ending June 26.

1 month agoCapital Market - Live
Spotlight
Spotlight
Wockhardt Ltd spurts 0.27%, gains for five straight sessions

Wockhardt Ltd rose for a fifth straight session today. The stock is quoting at Rs 2214, up 0.27% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.5% on the day, quoting at 23660.65. The Sensex is at 75637.53, down 0.65%. Wockhardt Ltd has added around 14.64% in last one month. Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has added around 1.46% in last one month and is currently quoting at 26675.5, up 0.72% on the day. The volume in the stock stood at 9.14 lakh shares today, compared to the daily average of 10.16 lakh shares in last one month.The PE of the stock is 108.36 based on TTM earnings ending June 26.

1 month agoCapital Market - Live
Spotlight
Spotlight
Wockhardt Ltd soars 6.61%, rises for third straight session

Wockhardt Ltd rose for a third straight session today. The stock is quoting at Rs 2079.6, up 6.61% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.28% on the day, quoting at 23940.4. The Sensex is at 76706.33, up 0.73%. Wockhardt Ltd has added around 3.66% in last one month. Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has added around 0.01% in last one month and is currently quoting at 26658.65, down 0.36% on the day. The volume in the stock stood at 20.57 lakh shares today, compared to the daily average of 7.03 lakh shares in last one month.The PE of the stock is 95.78 based on TTM earnings ending June 26.

1 month agoCapital Market - Live

Frequently asked questions

  1. The share price of WOCKPHARMA as on 3rd November 2026 is ₹1868. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Wockhardt Limited (WOCKPHARMA) share are
    • Past 1 week: 3.01%
    • Past 1 month: -10.40%
    • Past 3 months: -8.35%
    • Past 6 months: 30.46%
    • Past 1 year: 31.49%
    • Past 3 years: 678.80%
    • Past 5 years: 360.95%

  3. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Wockhardt Limited (WOCKPHARMA) is ₹30820.43 Cr as of 3rd November 2026.

  4. The 52-week high of Wockhardt Limited (WOCKPHARMA) is ₹2422.30 and the 52-week low is ₹1086.70.

  5. The P/E (price-to-earnings) ratio of Wockhardt Limited (WOCKPHARMA) is 108.50. The P/B (price-to-book) ratio is 5.84.

  6. Wockhardt Limited (WOCKPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  7. You can directly buy Wockhardt Limited (WOCKPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.